Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks , happy new year.
Does any body know if market is open on Monday. TA
i would call that investor a scam!
YMI- still holding.
http://www.nodeju.com/3965/lisa-rinna-celebs-cosmetic-disasters.html
this is what happens with fillers sometimes!!!
NOW, 18 cents away!!!!!!!
now the share price is 0.17 cents from your target. day to day price is not what you or i am looking at! on top of that tax loss selling is going on in the last few weeks.
We are looking at long term thing, and yes as you said in the past that company will be never be able to survive, it may be true. It may also be true that it will be very successul company. All we are debating here is the product and it's potential. your comparision of LAVIV with Sculptra is flawed just because they both are long term product.
you are loosing any respect by writing these kind of stuff.. base less, senseless.
LAVIV is FDA approved after extensive advisory panel. There are patients out there with great results for seven year. I don't know what to say? How can you say something baseless like this. it amazes me. Be rational with your stuff, please don't loose your respect by doing that.
Kipper , excellent summary!
Botox have to be done every 4 -6 months and after that you get plastic face. you pay 300- 700 bucks every time you go for botox.
Laviv is one time thing. effect lasts for years. Income level- everybody does not have same income, and so every body does not go to whole foods, but there are enough people who can afford it. long term you you still benefit after one time fees of around 3500. You cells are preserved and they can be used 10, 20 years after the original procedure and they still would be use ful.
happy new year to you too.
yup agree, 100%
That's why i said, it will need patience and it will take time to build the market. It is whole new category, it will take time for people to understand the benefits and to understand what it is. I am not saying it will be suceess for sure, but i am certainly hopeful.
I had to give that analogy because sometimes some people just dont understand these stuff and you have to explain them as simplistic way as you can!
regards.
Dude, No bobody is pumping and no body is saying it will be same like botox! they both are different products. everybody goes to walmart and kroger ( Like botox) but very few go the fresh market or whole foods. Still whole foods and fresh market are doing well. It will certainly take some time , but it will happen!!!!!!!!!!!
Kipper, you hit the nail on the head!
I think it will take some time and of course some financial support for Fcsc to come out of this difficult period , if they go through this period it will be very different story than many posters believe. We will see , it definitely requires patience.
Thank you good article
Agree and thank you for explanation
Ok got it. Thank you so much!!
I still think it is indirect dilution!I mean more shares in the market to trade.
Thanks, does that means more dilution!
Well , i wont make any presumption on the basis on just one day of action. tomorrow again , it may go in to the garbage like everyday.
WOW, magic fcsc closed green!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
ZGNX: GLTU
ZGNX:
Drug companies are working to develop a pure, more powerful version of the nation’s second most-abused medicine, which has addiction experts worried that it could spur a new wave of abuse.
The new pills contain the highly addictive painkiller hydrocodone, packing up to 10 times the amount of the drug as existing medications such as Vicodin. Four companies have begun patient testing, and one of them — Zogenix of San Diego — plans to apply early next year to begin marketing its product, Zohydro.
If approved, it would mark the first time patients could legally buy pure hydrocodone. Existing products combine the drug with nonaddictive painkillers such as acetaminophen.
Critics say they are especially worried about Zohydro, a timed-release drug meant for managing moderate to severe pain, because abusers could crush it to release an intense, immediate high.
“I have a big concern that this could be the next OxyContin,” said April Rovero, president of the National Coalition Against Prescription Drug Abuse. “We just don’t need this on the market.”
LIST: The Prescription Drug Overdose Epidemic, Plus 7 Other Health Stories to Watch in 2012
OxyContin, introduced in 1995 by Purdue Pharma of Stamford, Conn., was designed to manage pain with a formula that dribbled one dose of oxycodone over many hours.
Abusers quickly discovered they could defeat the timed-release feature by crushing the pills. Purdue Pharma changed the formula to make OxyContin more tamper-resistant, but addicts have moved onto generic oxycodone and other drugs that do not have a timed-release feature.
Oxycodone is now the most-abused medicine in the United States, with hydrocodone second, according to the Drug Enforcement Administration’s annual count of drug seizures sent to police drug labs for analysis.
The latest drug tests come as more pharmaceutical companies are getting into the $10 billion-a-year legal market for powerful — and addictive — opiate narcotics.
“It’s like the wild west,” said Peter Jackson, co-founder of Advocates for the Reform of Prescription Opioids. “The whole supply-side system is set up to perpetuate this massive unloading of opioid narcotics on the American public.”
The pharmaceutical firms say the new hydrocodone drugs give doctors another tool to try on patients in legitimate pain, part of a constant search for better painkillers to treat the aging U.S. population.
“Sometimes you circulate a patient between various opioids, and some may have a better effect than others,” said Karsten Lindhardt, chief executive of Denmark-based Egalet, which is testing its own pure hydrocodone product.
The companies say a pure hydrocodone pill would avoid liver problems linked to high doses of acetaminophen, an ingredient in products like Vicodin. They also say patients will be more closely supervised because, by law, they will have to return to their doctors each time they need more pills. Prescriptions for the weaker, hydrocodone-acetaminophen products now on the market can be refilled up to five times.
MORE: Could Medical Marijuana Reduce Patients’ Need for Painkillers?
Zogenix has completed three rounds of patient testing, and last week it announced it had held a final meeting with Food and Drug Administration officials to talk about its upcoming drug application. It plans to file the application in early 2012 and have Zohydro on the market by early 2013.
Purdue Pharma and Cephalon, a Frazer, Pa.-based unit of Israel-based Teva Pharmaceuticals, are conducting late-stage trials of their own hydrocodone drugs, according to documents filed with federal regulators. In May, Purdue Pharma received a patent applying extended-release technology to hydrocodone. Neither company would comment on its plans.
Meanwhile, Egalet has finished the most preliminary stages of testing aimed at determining the basic safety of a drug. The firm could have a product on the market as early as 2015 but wants to see how the other companies fare with the FDA before deciding whether to move forward, Lindhardt said.
Critics say they are troubled because of the dark side that has accompanied the boom in sales of narcotic painkillers: Murders, pharmacy robberies and millions of dollars lost by hospitals that must treat overdose victims.
Thousands of legitimate pain patients are becoming addicted to powerful prescription painkillers, they say, in addition to the thousands more who abuse the drugs.
Prescription painkillers led to the deaths of almost 15,000 people in 2008, more than triple the 4,000 deaths in 1999, the Centers for Disease Control and Prevention reported last month.
Emergency room visits related to hydrocodone abuse have shot from 19,221 in 2000 to 86,258 in 2009, according to data compiled by the Drug Enforcement Administration. In Florida alone, hydrocodone caused 910 deaths and contributed to 1,803 others between 2003 and 2007.
MORE: Are Doctors Really to Blame for the Overdose Epidemic?
Hydrocodone belongs to family of drugs known as opiates or opioids because they are chemically similar to opium. They include morphine, heroin, oxycodone, codeine, methadone and hydromorphone.
Opiates block pain but also unleash intense feelings of well-being and can create physical dependence. The withdrawal symptoms are also intense, with users complaining of cramps, diarrhea, muddled thinking, nausea and vomiting.
After a while, opiates stop working, forcing users to take stronger doses or to try slightly different chemicals.
“You’ve got a person on your product for life, and a doctor’s got a patient who’s never going to miss an appointment, because if they did and they didn’t get their prescription, they would feel very sick,” said Andrew Kolodny, president of Physicians for Responsible Opioid Prescribing. “It’s a terrific business model, and that’s what these companies want to get in on.”
Under pressure from the government, Purdue Pharma last year debuted a new OxyContin pill formula that “squishes” instead of crumbling when someone tries to crush it.
But Zogenix, whose drug is time-released but crushable, says there is not enough evidence to show that such tamper-resistant reformulations thwart abuse.
“Provided sufficient effort, all formulations currently available can be overcome,” Zogenix said in a written response to questions by The Associated Press.
MORE: A Brief History of OD’ing in America
At a conference for investors New York on Nov. 29, Zogenix chief executive Roger Hawley said the FDA was not pressuring Zogenix to put an abuse deterrent in Zohydro.
“We would certainly consider later launching an abuse-deterrent form, but right now we believe the priority of safer hydrocodone — that is, without acetaminophen — is a key priority for the FDA,” Hawley said.
FDA spokeswoman Erica Jefferson said the agency would not comment on its discussions with drug companies, citing the need to protect trade secrets.
Drug control advocates say they’re worried the U.S. government is too lax about controlling addictive pain medications. The United States consumes 99 percent of the world’s hydrocodone and 83 percent of its oxycodone, according to a 2008 study by the International Narcotics Control Board.
One 41-year-old loophole in particular has fed the current problem with hydrocodone abuse, critics say. The federal Controlled Substances Act, passed in 1970, puts fewer controls on combination pills containing hydrocodone and another painkiller than it does on the equivalent oxycodone products.
A Vicodin prescription can be refilled five times, for example, while a Percocet prescription can only be filled once.
The Drug Enforcement Administration and Food and Drug Administration have been studying whether to close this loophole since 1999 but have made no decision. Congress is now considering a bill that would force the agencies to tighten the controls.
“This is a problem that is fundamentally an oversupply problem,” said Jackson, the drug-control advocate. “The FDA has kind of opened the floodgates, and they refuse to recognize the mistakes made in the past.”
MORE: Taking Just a Little Too Much Tylenol Each Time Can Be Deadly
Pure hydrocodone falls into the stricter drug-control category than hydrocodone-acetaminophen medications, meaning patients would have to go to their doctors for a new prescription each time they needed more pills. But Jackson said that’s no guarantee against abuse, noting that dozens of unscrupulous doctors have been caught churning out prescriptions in so-called “pill mills.”
The Drug Enforcement Administration, which enforces controls on medicines along with the FDA, said it could not comment on drugs that have not yet been approved for sale.
However, Zogenix has acknowledged the abuse issue could become a liability.
“Illicit use and abuse of hydrocodone is well documented,” it said in a filing with the Securities and Exchange Commission in September. “Thus, the regulatory approval process and the marketing of Zohydro may generate public controversy that may adversely affect regulatory approval and market acceptance of Zohydro.”
Read more: http://healthland.time.com/2011/12/26/powerful-new-painkiller-has-addiction-experts-worried/#ixzz1hlmiVz5B
OT:
CBS/AP) As pharmaceutical companies are approaching the final stages of development for a new type of painkiller said to be 10 times stronger than Vicodin, addiction experts worry a new wave of abuse may soon follow.
PICTURES: Painkiller deaths: 15 states with highest rates
Four companies have begun patient testing on the pills which contain a pure version of the highly addictive painkiller hydrocodone, and one of them - Zogenix of San Diego - plans to apply early next year to begin marketing its product, Zohydro.
If approved, it would mark the first time patients could legally buy pure hydrocodone. Existing products combine the drug with nonaddictive painkillers such as acetaminophen.
Hydrocodone belongs to family of drugs known as opiates or opioids because they are chemically similar to opium. They include morphine, heroin, oxycodone, codeine, and methadone.
Critics are especially worried about Zohydro, a timed-release drug meant for managing moderate to severe pain, because abusers could crush it for an intense, immediate high.
"I have a big concern that this could be the next OxyContin," said April Rovero, president of the National Coalition Against Prescription Drug Abuse. "We just don't need this on the market."
OxyContin, introduced in 1995 by Purdue Pharma of Stamford, Conn., was designed to manage pain with a formula that dribbled one dose of oxycodone over many hours. Abusers quickly discovered they could defeat the timed-release feature by crushing the pills. Purdue Pharma changed the formula to make the pill more tamper-resistant, but addicts have moved onto generic oxycodone and other drugs that are not time-released.
Oxycodone is now the most-abused medicine in the U.S., with hydrocodone second, according to the Drug Enforcement Administration.
The latest drug studies come as more pharmaceutical companies are getting into the $10 billion-a-year legal market for powerful yet highly addictive opioid narcotics.
"It's like the wild west," said Peter Jackson, co-founder of Advocates for the Reform of Prescription Opioids. "The whole supply-side system is set up to perpetuate this massive unloading of opioid narcotics on the American public."
Pharmaceutical companies say the new drugs give doctors another tool to help patients in legitimate pain.
"Sometimes you circulate a patient between various opioids, and some may have a better effect than others," said Karsten Lindhardt, chief executive of Denmark-based Egalet, which is testing its own pure hydrocodone product.
Pure hydrocodone pills would avoid liver problems linked to high doses of acetaminophen, an ingredient in products like Vicodin, according to the drug companies. They also say patients will be more closely supervised because they will have to return to their doctors each time they need more pills. Prescriptions for the weaker, hydrocodone-acetaminophen products can be refilled up to five times.
Zogenix has completed three rounds of patient testing, and last week it announced it had held a final meeting with FDA officials to talk about its upcoming drug application. It plans to file the application in early 2012 and have Zohydro on the market by early 2013.
Purdue Pharma and Cephalon, a Frazer, Pa.-based unit of Israel-based Teva Pharmaceuticals, are conducting late-stage trials of their own hydrocodone drugs, according to documents filed with federal regulators. In May, Purdue Pharma received a patent applying extended-release technology to hydrocodone.
Egalet has finished the most preliminary stages of safety testing and could have a product on the market as early as 2015 but wants to see how the other companies fare with the FDA before deciding whether to move forward, Lindhardt said.
Critics are troubled because a new narcotic painkiller can lead to more murders, pharmacy robberies, and millions of dollars lost by hospitals to treat overdose victims. Thousands of legitimate pain patients are becoming addicted to powerful prescription painkillers, they say, in addition to the thousands more who abuse them illegally.
The CDC said last month that prescription painkillers caused 15,000 U.S. deaths in 2008, more than triple the 4,000 deaths in 1999.
Emergency room visits related to hydrocodone abuse have shot from 19,221 in 2000 to 86,258 in 2009, according to the DEA. In Florida alone, hydrocodone caused 910 deaths and contributed to 1,803 others between 2003 and 2007.
Opiates block pain but also unleash intense feelings of well-being and can create physical dependence. Withdrawal symptoms can be intense, causing cramps, diarrhea, muddled thinking, nausea and vomiting. After a while, opiates stop working, forcing users to take stronger doses.
"You've got a person on your product for life, and a doctor's got a patient who's never going to miss an appointment, because if they did and they didn't get their prescription, they would feel very sick," said Andrew Kolodny, president of Physicians for Responsible Opioid Prescribing. "It's a terrific business model, and that's what these companies want to get in on."
The U.S. consumes 99 percent of the world's hydrocodone and 83 percent of its oxycodone, according to a 2008 study by the International Narcotics Control Board.
happy holidays to you too!
NOW $ .19 to go. keep on counting.
How do u know for sure that fibrocell is hiring them. TA
Great video ron
AMRN_ Agree.
YMI-NOPE, that has nothing to do with partenership. the bottom line is they have far superior drug than JAKAFI AND that is what matters to partner.
With amrn, i dont have clue either, i got out at 16 bucks, so far my biggest gain. sorry to hear about your loss on amrn, right now i think does not make sense to sell amrn. with YMi, i dont know what is cvuban. can you please eloborate it so i can dig in to it.
YMI- Still holding. you know recently few brokrage house like roadman, roth and wells fargo upgraded it. Now one can assume that there is financing coming after these upgrads so that brokrage houses can get good fees on it. Short sellers might be shorting it in the anticipation of financing news. Now two things i would like to say about it.
1. it is 50 -50 financing and partnership or takover. even if it is financing it is still very undervalued IMO.
2. if partnership or take over happens it will be whole different ball game .
I am more than happy to hold for long term after decent phase II data on 166 patients. Have seen this before.
YMI - I THINK, BECAUSE OF ALL THE ANALYST UPGRADES RECENTLY, MARKET AND SHORT SELLERS ARE THINKING ABOUT POSSIBLE FINANCING COMING IN. EVEN IF THAT HAPPENS THE STOCK IS WAYYY UNDERVALUED.
IF PARTENRESHIP NEWS COMES IN SHORTS WILL GET CRUSHED LIKE A HOT POTATO.
thank you
BFR- YMI- do you know what price target, roth gave to YMI.
Yeah I remember that sngx thing as well , I missed the train . These data thing is really very very risk as you said
Agree sheff, I think I took very big risk sticking to the YMI through data , glad it was not bad.